Journal of Bone and Mineral Metabolism

, Volume 30, Issue 4, pp 434–438 | Cite as

Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw

  • Evelina Maines
  • Elena Monti
  • Francesco Doro
  • Grazia Morandi
  • Paolo Cavarzere
  • Franco Antoniazzi
Original Article

Abstract

Over recent years, several reports have been published on unusual cases of osteonecrosis of the jaw (ONJ) in adults using second- and third-generation nitrogen-containing bisphosphonates such as pamidronate, alendronate, risedronate and zoledronate, but no case has ever been reported either in children or in adult patients taking neridronate. Children and adolescents affected by osteogenesis imperfecta (OI) could belong to a high-risk group for ONJ because bone fragility in OI is associated with a connective tissue malfunction. The purpose of this study is to evaluate the incidence of ONJ in a pediatric population treated with neridronate for OI. A total of 102 pediatric patients with OI who received neridronate infusions for a mean of 6.81 years (SD ± 3.06 years) were clinically assessed for possible ONJ. Eligibility criteria for participation included patients between 1.2 and 24 years old who received cyclical neridronate infusions for at least 1 year. All the patients were reviewed to determine duration, dosage and cumulative dose of their bisphosphonate therapy and were examined clinically to assess their oral health status. We have not demonstrated any occurrence of ONJ in our patients. In conclusion, at the moment insufficient data are available to prove a greater risk of ONJ in children with OI than in children affected by other forms of bone fragility. However, cases may emerge in future because the risk of ONJ seems to be related to the cumulative dose and the duration of therapy.

Keywords

Intravenous neridronate Osteonecrosis of the jaw Osteogenesis imperfecta 

Abbreviations

ONJ

Osteonecrosis of the jaw

OI

Osteogenesis imperfecta

Notes

Conflict of interest

All authors have no conflicts of interest.

References

  1. 1.
    Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A (2011) Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet Part A 155:943–968CrossRefGoogle Scholar
  2. 2.
    Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F (2010) Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 6:367–381PubMedGoogle Scholar
  3. 3.
    Glorieux FH (2001) Osteogenesis imperfecta. A disease of the osteoblast. Lancet 358:S45Google Scholar
  4. 4.
    Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Min Res 20:758–763CrossRefGoogle Scholar
  5. 5.
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952PubMedCrossRefGoogle Scholar
  6. 6.
    Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tatò L (2006) Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149:174–179PubMedCrossRefGoogle Scholar
  7. 7.
    Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G (1997) Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131:622–625PubMedCrossRefGoogle Scholar
  8. 8.
    Rauch F, Plotkin H, Zeitlin L, Glorieux FH (2003) Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610–614PubMedCrossRefGoogle Scholar
  9. 9.
    Papapoulos SE (2008) Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22:831–847PubMedCrossRefGoogle Scholar
  10. 10.
    Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRefGoogle Scholar
  11. 11.
    Melo MD, Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136:1675–1681PubMedGoogle Scholar
  12. 12.
    Levin L, Laviv A, Schwartz-Arad D (2007) Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 138:1218–1220PubMedGoogle Scholar
  13. 13.
    Ruggiero SL, Drew SJ (2007) Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86:1013–1021PubMedCrossRefGoogle Scholar
  14. 14.
    Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF (2009) Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 140:61–66PubMedGoogle Scholar
  15. 15.
    Mattano LA Jr, Sather HN, Trigg ME, Nachman JB (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol 18:3262–3272PubMedGoogle Scholar
  16. 16.
    Niinimäki RA, Harila-Saari AH, Jartti AE, Seuri RM, Riikonen PV, Pääkkö EL, Möttönen MI, Lanning M (2008) Osteonecrosis in children treated for lymphoma or solid tumors. J Pediatr Hematol Oncol 30:798–802PubMedCrossRefGoogle Scholar
  17. 17.
    Carey JJ, Palomo L (2008) Bisphosphonate and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med 75:871–879PubMedCrossRefGoogle Scholar
  18. 18.
    Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRefGoogle Scholar
  19. 19.
    Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376Google Scholar
  20. 20.
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR et al (2007) American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491Google Scholar
  21. 21.
    Ruggiero S, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534PubMedCrossRefGoogle Scholar
  22. 22.
    Mariotti A (2008) Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 72:919–929PubMedGoogle Scholar
  23. 23.
    Brown JJ, Ramalingam L, Zacharin MR (2008) Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol 68:863–867CrossRefGoogle Scholar
  24. 24.
    Malmgren B, Åström E, Söderhäll S (2008) No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37:196–200PubMedCrossRefGoogle Scholar
  25. 25.
    Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 153:719–720PubMedCrossRefGoogle Scholar
  26. 26.
    Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS (2007) Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother 41:276–284PubMedCrossRefGoogle Scholar
  27. 27.
    Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365–383PubMedCrossRefGoogle Scholar
  28. 28.
    Duan X, Xia Z, Zhang H, Quijano M, Dobson R, Barnett B, Triffitt J, Dunford J, Ebetino F, Russel RG (2010) Determination of the relative bone mineral-binding affinities of bisphosphonates by using hydroxyapatite-column chromatography combined with mass spectrometric analysis. Bone 46:S23CrossRefGoogle Scholar
  29. 29.
    Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033PubMedCrossRefGoogle Scholar
  30. 30.
    American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137:1144–1150Google Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2011

Authors and Affiliations

  • Evelina Maines
    • 1
  • Elena Monti
    • 1
  • Francesco Doro
    • 1
  • Grazia Morandi
    • 1
  • Paolo Cavarzere
    • 1
  • Franco Antoniazzi
    • 1
  1. 1.Department of Life Sciences and Reproduction Sciences, Pediatric ClinicUniversity of Verona, General Hospital “Giambattista Rossi”VeronaItaly

Personalised recommendations